Nachrichten zur Exelixis Inc. Aktie

Image source: The Motley Fool. DATEMonday, July 28, 2025 at 9:00 p.m. ETCALL PARTICIPANTSPresident & CEO — Michael M. MorrisseyChief Financial…

…

…

Key Points- Non-GAAP earnings per share of $0.75 in Q2 FY2025 easily beat expectations, while GAAP revenue was slightly below…

After-hours movers: Western Union, Whirlpool, Exelixis, and more…

Exelixis shares tumble as revenue miss and weak guidance disappoint…

Key PointsExelixis most important product should continue driving strong financial results through the end of the decade.The oncology specialist is…

Key PointsPfizer is slowly building a foundation that will help its business recover from recent headwinds.Encouraging developments on the clinical…

EXEL, LYFT, and KGC see broker upgrades and strong 2025 earnings growth forecasts amid volatile market conditions.…

Whats the biggest misconception about investing? The idea that you need a lot of money to get started is certainly…

Geschäftstreiber: Der US-Konzern Exelixis (EXEL) hat sich auf die Entwicklung von Wirkstoffen und Medikamenten im Bereich Onkologie spezialisiert. Mit  Cabometyx…

SFM, RGLD, TRI, WWD and EXEL are non-tech Nasdaq standouts with strong ranks, rising estimates and double-digit gains in 2025.…

Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a…

Palomar Holdings, Exelixis and Olo stocks all boast top Zacks Ranks, reasonable valuations and strong price momentum…

Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies…

When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with…

Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after…

ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Exelixis Inc. (EXEL) on Tuesday...…

Exelixis stock jumped late Thursday after the top-notch biotech company easily beat first-quarter profit expectations.…

One of the great things about equity markets is that you dont need a fortune to get started. Though strong…

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value.…

Mit fast 10 Mio. Todesfällen pro Jahr ist Krebs eine der häufigsten Todesursachen überhaupt. Deshalb wird in der Medizin aktuell…

Analysts are bullish on both Carpenter Technology and Exelixis stock. Both are in bases with proper buy points in a…

Exelixis überzeugte am 11. Februar mit starken Zahlen zum 4. Quartal, die sowohl beim Umsatz mit 566,8 Mio. USD als…

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that its making a…

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter…

Some think investing in stocks requires substantial start-up capital, but thats false. Even with a modest sum, like $40, investors…

Mehrere Biotechfirmen überraschen gerade mit ihren vorläufigen Quartalsergebnissen. Hier zählt nun auch Exelixis (EXEL) nach dem bereits erfolgreichen Big-Picture-Breakout zu…

Brookline Capital sets $40 target on Exelixis stock with Buy rating…

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark,…

Das Biotechunternehmen Exelixis (EXEL) hat sich auf Tyrosinkinase-Inhibitoren zur Krebsbehandlung spezialisiert. Diese können Enzyme blockieren und damit das Tumorwachstum sowie…

InterDigital, Futu Holdings and Exelixis are all stocks with reasonable valuations and bullish catalysts…

Über Exelixis habe ich das letzte Mal nach den starken Q2-Zahlen im Juli berichtet. Die Aktie konnte in den letzten…

…

…

Genpact, MPLX, Exelixis, Paramount Global and H&R Block have been highlighted in this Screen of The Week article.…

Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.…

…

…

…

Exelixis (NASDAQ:EXEL) has had a great run on the share market with its stock up by a significant 5.1% over…

Exelixis director Garber Alan M sells shares worth over $460k…